Experimental tissue-repair peptide
No FDA-approved BPC-157 product.
People seek BPC-157 for joint and tendon recovery, healing after injury, and gut symptoms. Most of the research is in animals or the laboratory. Small human reports offer early signals, but they do not establish tissue repair, treatment of gut disease, or a reliable self-use regimen.123
In a small retrospective report, 11 of 12 people given BPC-157 alone reported improved knee pain. There was no control group or imaging to show that tendons, ligaments, or cartilage had healed.1
Community use extends to muscle, tendon, and ligament injuries. Those broader healing claims go beyond what the human report can demonstrate.23
Community reports focus on gut irritation, ulcers, and intestinal inflammation. A validated human treatment schedule or demonstrated clinical benefit for these uses was not verified.823
15 residues · N → C4
G–E–P–P–P–G–K–P–A–D–D–A–G–L–VFree N- and C-termini in the cited identity.
Free peptide identity; acetate and other salt formulations have additional components.
Pharmacokinetics · How quickly the compound clears.
Time for the level to fall by half.
After five half-lives in this model.
Animal data · Single intravenous administration22
Animal measurements do not establish a human half-life. Mean intact BPC-157 elimination half-life after a single IV administration. This is an animal measurement, not a human prediction.
Illustrative model using animal measurements.
No. Effects can end sooner or last longer than the measured level. This curve estimates decline from a starting reference level; it does not set a dosing schedule.
Sprague-Dawley rats; n = 6
The model uses a constant half-life. It starts from a reference level, not the moment of administration, and excludes absorption, repeated doses, and metabolites. About 3% remains after five half-lives.
Time for the level to fall by half.
After five half-lives in this model.
Animal data · Single intravenous administration22
Animal measurements do not establish a human half-life. Intact-peptide elimination in dogs after a single IV administration. Species and route differ from human community use.
Illustrative model using animal measurements.
No. Effects can end sooner or last longer than the measured level. This curve estimates decline from a starting reference level; it does not set a dosing schedule.
Beagle dogs; n = 6
The model uses a constant half-life. It starts from a reference level, not the moment of administration, and excludes absorption, repeated doses, and metabolites. About 3% remains after five half-lives.
Time for the level to fall by half.
After five half-lives in this model.
Unverified reference estimate · Source page: Injectable. Exact PK route not verified.21
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
Illustrative scenario using an unverified reference estimate.
No. Effects can end sooner or last longer than the measured level. This curve estimates decline from a starting reference level; it does not set a dosing schedule.
Not established by the reference estimate. The reference attributes this to Sikiric et al. various studies; that attribution is unverified.
The source reports a peak time of 1 hr; this is unverified and is not part of the curve.
The model uses a constant half-life. It starts from a reference level, not the moment of administration, and excludes absorption, repeated doses, and metabolites. About 3% remains after five half-lives.
Time for the level to fall by half.
After five half-lives in this model.
Unverified reference estimate · Source page: Oral. Exact PK route not verified.21
Secondary-source estimate shown for this route; the population and exact formulation have not been independently matched to a human PK study. The source’s clearance label is approximately five half-lives, not zero remaining drug or a duration of effects.
Illustrative scenario using an unverified reference estimate.
No. Effects can end sooner or last longer than the measured level. This curve estimates decline from a starting reference level; it does not set a dosing schedule.
Not established by the reference estimate. The reference attributes this to Sikiric et al. various studies; that attribution is unverified.
The source reports a peak time of 1 hr; this is unverified and is not part of the curve.
The model uses a constant half-life. It starts from a reference level, not the moment of administration, and excludes absorption, repeated doses, and metabolites. About 3% remains after five half-lives.
11 of 12 BPC-only respondents reported improvement; retrospective telephone follow-up cannot establish causation.1
The IV pilot reported no adverse events or measured biomarker changes. Its size and brief follow-up cannot establish safety.2
Reference/community sequence: pain/inflammation or digestive comfort; repair/barrier changes; maximum/systemic benefits. Not validated human recovery estimates.23
These are reported timelines, not a prediction of your response.
Compare study doses and reported practices. Community and reference reports are unvalidated.
Scroll to compare all columns →
| Goal | Dose | Frequency | Route | Duration | Source |
|---|---|---|---|---|---|
| Short-term infusion safetyHuman studyTwo adults previously exposed to IV BPC-157 | 10 mg | Once on day 1 | IVIntravenous infusion over one hour | Day 1 | 2 |
Population Two adults previously exposed to IV BPC-157 Context Experimental clinic exposure; no control group and no efficacy endpoint. Source dose wording 10 mg on day 1; 20 mg on day 2 | |||||
| Short-term infusion safetyHuman studyTwo adults previously exposed to IV BPC-157 | 20 mg | Once on day 2 | IVIntravenous infusion over one hour | Day 2 | 2 |
Population Two adults previously exposed to IV BPC-157 Context Experimental clinic exposure; no control group and no efficacy endpoint. Source dose wording 10 mg on day 1; 20 mg on day 2 | |||||
| Tendon/Joint healingReference report | 250-500 mcg | 1-2x daily | SubQSubQ near injury | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Serious injuryReference report | 500-1000 mcg | 2x daily | SubQSubQ near injury | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| General healingReference report | 250-500 mcg | 1-2x daily | SubQ | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording SubQ or IM Source tabs Injectable | |||||
| General healingReference report | 250-500 mcg | 1-2x daily | IM | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source route wording SubQ or IM Source tabs Injectable | |||||
| MaintenanceReference report | 250 mcg | 1x daily | SubQ | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Injectable | |||||
| Gastric protectionReference report | 500 mcg-1 mg | 1-2x daily | OralOral (empty stomach) | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| General healingReference report | 1-2 mg | 1-2x daily | OralOral (empty stomach) | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| Ulcer preventionReference report | 500 mcg | 2x daily | OralOral (empty stomach) | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
| MaintenanceReference report | 500 mcg | 1x daily | OralOral (empty stomach) | 4-12 weeks | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source tabs Oral | |||||
No protocols match these filters.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Empty stomach preferred
Empty stomach, 30 min before meals
FDA flags immunogenicity and peptide-impurity concerns.
3A two-person, three-day observation cannot quantify uncommon or long-term adverse effects.
2The knee report had no control group or objective tissue-healing measure.
1The assessment describes injection-site reactions, shortness of breath and a pigmentation reaction with a BPC-157/TB-500 product; causality and ingredient attribution remain limited.
7Persistent redness, infection, swelling/rash, severe headache/dizziness, worsening digestion or abdominal pain need assessment.
Blood-thinner interactions and pregnancy/lactation safety unresolved.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Interaction evidence limited.23
Reference report · Evidence context: Caution claimHealing rationale.23
Reference report · Pep-Pedia label: SynergisticNo validated combination.23
Reference report · Pep-Pedia label: CompatibleGH-receptor rationale.23
Reference report · Pep-Pedia label: SynergisticGH-receptor rationale.23
Reference report · Pep-Pedia label: SynergisticDifferent claimed receptor targets; combination untested.23
Reference report · Pep-Pedia label: CompatibleReported repair/fat-metabolism pairing; safety and efficacy unestablished.23
Reference report · Pep-Pedia label: CompatibleProposed tissue-repair/energy-metabolism complement; untested.23
Reference report · Pep-Pedia label: CompatibleFour patients in the knee report received BPC-157 with thymosin β4. That uncontrolled subgroup cannot establish an interaction, synergy, or safety.1
Research contextNo matching interactions. Try another name or filter.
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Enter an amount to calculate its volume and device setting.
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗The IV pilot used saline infusion; it provides no validated home-vial preparation or storage rule.29
Each study dose was diluted in 250 mL normal saline and infused in a clinic. This is a description of that experiment.2
The cited catalog identifies acetate quantities, not a clinically validated bacteriostatic-water volume or beyond-use date.9
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Pep-Pedia distinguishes mixed solution from unopened dry powder.
The source describes gentle mixing and avoiding vigorous shaking.
The source also claims multi-year dry-powder stability without a product-specific stability study.
The oral section describes capsules or measured powder, not vial reconstitution.
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Device units measure volume. Concentration determines the amount in mg.
Documented 1-unit V2 models
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
100 units = 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
mL syringes and calibrated pipettes
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Whether benefits exceed placebo, natural recovery, or usual treatment.1
Limited research. Some human research, but the checked evidence is small, early, narrow, inconsistent, or has important quality limitations. One trial does not establish broad benefit or safety.
Evidence definitions →An experimental 15-amino-acid peptide studied mainly in laboratory and animal injury models. Small uncontrolled human reports do not establish that it repairs tendons, treats gut disease, or is safe for self-injection.
Other names: BPC157 · BPC 157 · Body Protection Compound 157 · PL 14736
No FDA-approved BPC-157 product.
H-GEPPPGKPADDAGLV-OH4
15 amino acids · 1,419.53 Da
Gly-Lys-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-ValReference description; checked chemical identity takes precedence when available.23
Angiogenesis, collagen and growth-factor signaling are proposed mechanisms; human route superiority is unestablished.23
In a retrospective clinic report, 11 of 12 patients receiving BPC-157 alone reported improvement after a knee injection. There was no control group, standardized functional assessment, or imaging confirmation of healing.
1Two adults previously exposed to BPC-157 reported no side effects after two IV infusions; measured blood markers showed no meaningful changes. This sample cannot establish safety or rule out uncommon harms.
2FDA identifies immunogenicity, impurity/characterization concerns and insufficient proposed-route safety information for compounded BPC-157.
FDA compounding safety statement; checked24Joint and tendon recovery. A small retrospective knee-pain report exists; it does not establish structural tissue repair.1
Wound / tissue. Tendon, ligament, muscle and vascular repair claims.23
Neurological. Brain ischemia, spinal injury, peripheral nerves, cognition and stress-response hypotheses.23
Gastrointestinal. Gastric/duodenal ulcers, intestinal inflammation, mucosal repair and barrier function; oral/systemic claims exceed established human evidence.23
Pep-Pedia describes injury and gut-related use. Its protocol tables are secondary reports, not results of a dose-finding trial.8
No representative sample or verified outcomes supports these schedules; dose, product identity, co-use, and rehabilitation vary.
Additional recent evidence was checked, including FDA assessment: BPC-157 free base and acetate. See individual source summaries for findings and limitations.
AI-prepared summaries. Independent medical editorial review is pending.
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Number of responses to this question: not disclosed.
The source hides 9 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 22 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 28 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 12 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
The source displays “3834 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
Original sources and review status. Open a reference to read its summary.
Retrospective telephone follow-up: 11 of 12 BPC-only recipients reported pain improvement. No comparator or objective healing endpoint; a hypothesis-generating case series.
In a retrospective clinic report, 11 of 12 patients receiving BPC-157 alone reported improvement after a knee injection. There was no control group, standardized functional assessment, or imaging confirmation of healing.
Two previously exposed adults received 10 mg then 20 mg IV on consecutive days. No reported adverse effects or tested biomarker changes; the tiny, brief study cannot establish general safety.
Two adults previously exposed to BPC-157 reported no side effects after two IV infusions; measured blood markers showed no meaningful changes. This sample cannot establish safety or rule out uncommon harms.
FDA identifies unresolved human safety and product-characterization concerns for BPC-157.
Registry entry for the 15-residue free peptide; a salt or excipient-containing powder has a different total composition.
Parent BPC-157 cleared rapidly in rat and dog IV/IM experiments. These data do not provide a human half-life.
Parent BPC-157 cleared rapidly in rat and dog IV/IM experiments. These data do not provide a human half-life.
Pep-Pedia bibliography · Checked 2026-10-12
FDA reviewed sparse clinical studies and route-specific safety gaps; spontaneous adverse-event reports cannot establish event rates or causality.
Additional research · Checked 2026-10-12
The profile publishes commonly discussed schedules. It is used here to document community conventions, not validate benefit or dosage.
Catalog identifiers include 5 mg and 10 mg research quantities. A label amount is not a dose, clinical approval, or verification of an individual batch.
Pep-Pedia reports: Rat stomach-injury models showed less ulcer damage and improved mucosal repair across tested conditions.
Reported population / model
Rats
Reported study details
Multiple routes tested · Various durations · Cytoprotective effects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: The animal toxicology report describes no serious treatment-related findings under its test conditions; that does not establish human safety.
Reported population / model
Multiple species
Reported study details
Up to 1000 μg/kg · 90 days · Comprehensive toxicology
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Injured rats reportedly recovered more function and had less spinal tissue damage during 30 days of treatment.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 30 days · Improved functional recovery
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Laboratory findings linked BPC-157 to increased VEGFR2 activity and blood-vessel formation; clinical benefit remains unestablished.
Reported population / model
In vitro and in vivo
Reported study details
Various concentrations · VEGFR2 activation measured
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Rat quadriceps injuries reportedly showed improved tissue appearance, inflammation measures and function.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 28 days · Enhanced muscle regeneration
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Pep-Pedia reports: Transected rat Achilles tendons reportedly recovered better mechanical and functional measures; this is not evidence for a human regimen.
Reported population / model
Rats
Reported study details
10 μg/kg i.p. daily · 14 days · Significant improvement in tendon healing
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
Lists a half-life of 4 hrs and a peak time of 1 hr. Stated attribution: Sikiric et al. various studies. This 4-hour reference claim differs from measured intact-peptide elimination in rats and dogs (under 30 minutes). It is not a validated human half-life. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
Single IV dosing produced a mean intact-peptide elimination half-life of 15.2 minutes in rats and 5.27 minutes in dogs. IV/IM experiments reported values below 30 minutes. These animal measurements do not supply a human half-life or an effect duration.
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
FDA identifies immunogenicity, impurity/characterization concerns and insufficient proposed-route safety information for compounded BPC-157.
FDA identifies immunogenicity, impurity/characterization concerns and insufficient proposed-route safety information for compounded BPC-157.
Additional primary-source check · Checked 2026-10-12